Shanghai Gefimu Biopharmaceutical Technology

Shanghai Gefimu Biopharmaceutical Technology is a clinical-stage biotechnology company dedicated to developing next-generation small molecule drugs for cancer and autoimmune diseases. The company utilizes a proprietary structure-based drug discovery platform to address challenging targets, with a particular focus on the RAS/MAPK signaling pathway and protein-protein interactions. Its lead candidate, GFM-1001, is a potent and selective SHP2 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Gefimu's pipeline also includes promising programs targeting SOS1 and other key nodes in oncogenic signaling. Based in Shanghai, the company is supported by a team of experienced drug hunters and leading venture capital firms. The firm aims to provide first-in-class or best-in-class therapeutic solutions for patients with high unmet medical needs.